



Engage with ASGCT

[asgct.org](https://www.asgct.org)



Introduction - American Society of Gene & Cell Therapy

History

ASGCT was established in 1996 by Dr. George Stamatoyannopoulos, professor of medicine at the University of Washington's School of Medicine, and a group of the country's leading researchers in gene therapy. With over 4,600 members in the United States and worldwide, today ASGCT is the largest association of individuals involved in gene and cell therapy research.

Mission and Vision

The mission of ASGCT is to advance knowledge, awareness, and education leading to the discovery and clinical application of genetic and cellular therapies to alleviate human disease. ASGCT's strategic vision is to be a catalyst for bringing together scientists, physicians, patient advocates, and other stakeholders to transform the practice of medicine by incorporating the use of genetic and cellular therapies to control and cure human disease.

4,600+ Members

ASGCT is the primary professional membership organization for gene and cell therapy. The Society's members are scientists, physicians, patient advocates, and other professionals. Our members work in a wide range of settings including universities, hospitals, government agencies, foundations, and biotechnology and pharmaceutical companies. [Learn more about membership and join here!](#)

Website

Visit our website at asgct.org to learn more and to stay up-to-date with the latest news from ASGCT.

Board of Directors and Officers

Beverly Davidson, Ph.D., President
Hans-Peter Kiem, M.D., Ph.D., President-Elect
Jeffrey Chamberlain, Ph.D., Vice President
Terence R. Flotte, M.D., Secretary
Paloma Giangrande, Ph.D., Treasurer
Hildegard Büning, Ph.D.
Philip Gregory, D.Phil.
Anastasia Khvorova, Ph.D.
Marcela Maus, M.D., Ph.D.
Maritza McIntyre, Ph.D.
Federico Mingozzi, Ph.D.
Maria-Grazia Roncarolo, M.D.
Rayne Rouse, M.D.
Matthew Wilson, M.D., Ph.D.
Stephen J. Russell, M.D., Ph.D., Immediate Past President
Roland W. Herzog, Ph.D., Ex-Officio
[Learn more here about our leadership!](#)

Standing Committees

[Click here to view](#) ASGCT's 18 standing committees that determine the great majority of the Society's programs. Once a member, you have the ability to [self-nominate to serve on a committee](#) by the submission deadline at the end each January.

Engage with ASGCT Year-Round



**Molecular Therapy
Family of Journals**



Patient Education



Clinical Trials Finder



Policy Summit



Annual Meeting



**International Oncolytic
Virus Conference**



Grants & Awards



Career Center



**Professional
Development Cafés**



**Banner Ads in The
Vector E-Newsletter**



**Featured Job
Postings**

Click on the icons to learn more!

*Educational
Resources*

Events

*Support Future
Leaders*

Advertise

Annual Meeting

Join ASGCT for the field's premier event featuring cutting edge science with leaders from academia, medicine, industry, advocacy, and more. **The 25th Annual Meeting will take place May 16-19, 2022 in Washington, D.C.**

Sponsor/Exhibit


ASGCT will offer a variety of sponsorship, exhibit, and advertisement opportunities for you to maximize your presence in front of the gene and cell therapy audience.

The official 2022 prospectuses and exhibit hall floorplan will be released to the public later this year. Please check this [page](#) for the latest updates.

To be notified via email when the prospectuses are formally released, please email Rita Fadness (rfadness@asgct.org) to be added to the list.

Attendance

Is global and growing!



2021 Attendee Demographics

[Click here to download the full report.](#)

Attendee Location

- 42 Countries Represented
- 20% Attendees were from outside the U.S.

Organization Type

- 65% Industry
- 25% Academic
- 10% Other (Government, Non-Profit, Regulatory, etc)

Primary Attendee Roles

- 58% Scientist/R&D
- 14% Executive/Organization Leader
- 7% Student/Trainee
- 4% Business Development
- 3% Physician or other provider
- 3% Regulatory
- 2% Marketing
- 9% Other

34% of attendees were decision-makers for organization.

[Click here to visit our official Annual Meeting website.](#)

Policy Summit and Advocacy Efforts

The Society provides educational programming that connects policy and industry thought leaders with corporate, government relations, market access, regulatory, and scientific professionals. **The hybrid 2021 Policy Summit will be held September 22-24 in Washington D.C.**

▶ [2021 Policy Summit Agenda](#)

▶ [2021 Sponsors](#)

▶ [2020 Policy Summit Agenda](#)

▶ [2019 Policy Summit Agenda](#)

Initiatives Your Funding Supports

- Advocacy of coverage, reimbursement, and new payment models for gene and cell therapies
- Recommendations for streamlined regulation of safe and effective products
- Promotion of newborn screening policies that facilitate early diagnosis and treatment
- Support for robust NIH and FDA funding levels
- Education of Hill members and staff on gene and cell therapy and relevant policy issues

The ASGCT Advocacy Program is Built Upon Four Policy Priorities:

- 1 Patient access to approved gene and cell therapies through support of:
 - Payment policies that address access challenges
 - Expedited access to newborn screening for conditions treated by approved therapies
 - Enhanced global development of, and access to, gene and cell therapies
- 2 Regulatory processes that facilitate the efficient development of safe and effective therapies
- 3 Robust federal funding for basic and translational research in the field
- 4 Responsible, ethical use of these technologies

[Click here learn more about ASGCT's advocacy efforts and priorities.](#)


Global Access to Gene Therapies

ASGCT is working to foster equitable access to gene and cell therapies on a global scale; increase inclusion of global audiences into its existing programming; and broaden its global membership and engagement.

Initiatives Your Funding Supports

- Creating resources and programming for audiences outside of the US
- Encourage clinical trial development in middle-income countries with burgeoning regulatory frameworks that can support gene therapy
- Increasing awareness of the state of the gene therapy field through partnered educational programming with local institutions in low-income countries
- Provide research funding and training opportunities for researchers in their home countries

▶ **Want to learn more? Visit our website [here!](#)**



Patient Education

The ASGCT Patient Education Program was initiated in 2018. The resources numbered below are developed by the ASGCT Patient Outreach Committee in coordination with patient advocacy groups and stakeholders. Their goal is to make accurate, reliable, and accessible information about gene and cell therapies available to patients and the public. [Watch this video to learn more!](#)

1 Gene Therapy 101

2 Disease Treatments

3 Clinical Trials

4 Patient Journey

4 COVID-19 Vaccines

Patient Education resources include detailed overviews, videos, infographics, and webinars!

Support The Program


Sponsor ASGCT's Patient Education initiative to receive exposure on our [microsite listing](#) of supporters.

Annual Video Support

Sponsor patient-focused short videos and content to receive logo recognition at the end of a specific video. ASGCT is solely responsible for the content.

2021 Video Topics:

- Gaucher Disease
- GM1/GM2
- Gene Editing
- Wilson Disease



[Click here to visit the Patient Education site.](#)

Grants and Awards

Career Development Awards

Supports members whose careers in gene and cell therapy are working toward independence. In 2020, six recipients received grants of \$50,000 with awards totaling \$300,000 in each of the following six broad categories:

- Viral Vector Development
- Gene Targeting and Gene Correction
- Oligonucleotide Therapeutics
- Synthetic/Molecular Conjugates and Physical Methods for Delivery of Gene Therapeutics
- Cell Therapies
- Immunological Aspects of Gene Therapy and Vaccines

Support the 2022 CDA awards!

Organizations can sponsor the awards without any influence on the content of the program or the selection of the award recipient.


Diversity and Inclusion Awards

In June 2020, ASGCT made a commitment to promoting justice and equity in gene and cell therapy research. These new funding opportunities include the creation of the Society's first two fellowship awards, which will support underrepresented populations, including minorities, in gene and cell therapy, and the introduction of an award in support of research on conditions disproportionately impacting minority populations.

- Underrepresented Minority Fellowship Award in Gene and Cell Therapy for Oncology
- Underrepresented Population Fellowship Award in Gene and Cell Therapy for Any Indication
- Award for Research on Conditions Disproportionately Affecting Minorities
- Mentorship Award Program

Support the 2022 Diversity and Inclusion Awards!

Organizations can sponsor the awards without any influence on the content of the program or the selection of the award recipient.



[Click here to view more awards.](#)

Career Center

Overview

Are you looking to promote an open position at your company? Consider promoting it on the ASGCT Career Center where job seekers search for great opportunities with industry, government, and academic organizations.

[Enter the Career Center here.](#)

Benefits

- Discounts on posting for ASGCT members!
- Manage jobs and track your applicants right from our platform.
- Set up a profile for your company with your logo, contact information, website, video and social media pages.

Metrics

70.6	Jobs active per month
21.25	New jobs posted each month
432.7	Average number of job views per month

Numbers above are based on metric averages from July 2020-June 2021.

[Home](#) [Search](#) [Directory](#) [Contact Us](#) [Pricing](#)

[Post a Job](#) [Register](#) [Sign In](#)

ASGCT Career Center

[Find a Job](#)

Advertise in The Vector, ASGCT's Monthly E-Newsletter

1 Hyperlinked Banner Ads

Promote your company, products, services, a webinar series, event, etc!

The Vector features the newest discoveries and clinical applications of genetic and cellular therapies, public policy insights, industry news, and updates about the Annual Meeting.

The Vector reaches members who work in universities, hospitals, government agencies, foundations, biotechnology and pharmaceutical companies.

Specs and Placement

Hyperlinked horizontal banner ad dimensions: 650 x 150 pixels. ASGCT accepts up to four banner ads per issue. Advertisers are welcome to supply tracking URLs. Placement is based on a first-come, first-served basis.



2 Featured Job Postings

Recruit and connect with top gene and cell therapy job seekers by promoting open job(s) in The Vector's dedicated Career Center section!

Placement

In each monthly issue, there is space for a total of eight hyperlinked job postings.

E-Newsletter Stats

Current Recipients: 4,600+

Average open rate: 22.8%

Average click-to-open rate: 11.3%

Rate Card

For more information and to purchase ads please visit [The Vector](#) and [The Vector Ad Rates](#).

Let's Connect

Stay up-to-date with ASGCT by connecting with us online!

 **Facebook**
www.facebook.com/ASGCTherapy

 **Twitter**
[@ASGCTherapy](https://twitter.com/ASGCTherapy)

 **Instagram**
www.instagram.com/asgctherapy

 **LinkedIn**
American Society of Gene and Cell Therapy

 **Website**
www.asgct.org

Next Steps

Interested in any of the support opportunities listed in this document? Please reach out to Laura Gallagher, Director of Engagement, at lgallagher@asgct.org to learn more.

Thank you for your support and interest in ASGCT!